Neurocrine Biosciences (NBIX) Scheduled to Post Quarterly Earnings on Wednesday

Neurocrine Biosciences (NASDAQ:NBIX) is scheduled to be posting its quarterly earnings results before the market opens on Wednesday, May 1st. Analysts expect Neurocrine Biosciences to post earnings of $1.04 per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

Neurocrine Biosciences (NASDAQ:NBIX) last issued its earnings results on Wednesday, February 7th. The company reported $1.44 earnings per share for the quarter, beating analysts’ consensus estimates of $1.13 by $0.31. Neurocrine Biosciences had a return on equity of 12.85% and a net margin of 13.23%. The business had revenue of $515.20 million during the quarter, compared to analyst estimates of $518.52 million. During the same period in the previous year, the company posted $0.88 EPS. Neurocrine Biosciences’s revenue was up 25.0% on a year-over-year basis. On average, analysts expect Neurocrine Biosciences to post $5 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Neurocrine Biosciences Trading Up 2.1 %

NBIX opened at $138.89 on Tuesday. The company has a market capitalization of $13.82 billion, a price-to-earnings ratio of 57.39 and a beta of 0.25. Neurocrine Biosciences has a 12-month low of $89.04 and a 12-month high of $148.37. The business’s fifty day simple moving average is $136.76 and its 200-day simple moving average is $128.24.

Insiders Place Their Bets

In other news, insider David W. Boyer sold 456 shares of the company’s stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $141.96, for a total value of $64,733.76. Following the sale, the insider now owns 4,894 shares in the company, valued at $694,752.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Neurocrine Biosciences news, CEO Kevin Charles Gorman sold 2,707 shares of the company’s stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $140.69, for a total value of $380,847.83. Following the completion of the transaction, the chief executive officer now owns 502,188 shares in the company, valued at $70,652,829.72. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider David W. Boyer sold 456 shares of the firm’s stock in a transaction dated Tuesday, February 6th. The shares were sold at an average price of $141.96, for a total value of $64,733.76. Following the sale, the insider now owns 4,894 shares in the company, valued at $694,752.24. The disclosure for this sale can be found here. In the last three months, insiders have sold 186,994 shares of company stock valued at $25,806,409. Company insiders own 4.30% of the company’s stock.

Analysts Set New Price Targets

NBIX has been the topic of several research reports. Barclays lifted their price objective on shares of Neurocrine Biosciences from $145.00 to $150.00 and gave the company an “overweight” rating in a report on Tuesday, January 23rd. Oppenheimer reissued an “outperform” rating and issued a $200.00 price target on shares of Neurocrine Biosciences in a research report on Wednesday, April 24th. Wedbush reaffirmed an “outperform” rating and set a $147.00 price objective on shares of Neurocrine Biosciences in a research report on Wednesday, April 17th. Mizuho lifted their price objective on shares of Neurocrine Biosciences from $116.00 to $140.00 and gave the stock a “neutral” rating in a research report on Thursday, February 8th. Finally, Citigroup decreased their target price on shares of Neurocrine Biosciences from $141.00 to $140.00 and set a “neutral” rating for the company in a research report on Thursday, February 8th. Six equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $142.38.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.